Predictive factors for urinary toxicity after iodine-125 prostate brachytherapy with or without supplemental external beam radiotherapy

Eriguchi, Takahisa; Yorozu, Atsunori; Kuroiwa, Nobuko; Yagi, Yasuto; Nishiyama, Toru; Saito, Shiro; Toya, Kazuhito; Hanada, Takashi; Shiraishi, Yasuyuki; Ohashi, Toshio; Shigematsu, Naoyuki

doi:10.1016/j.brachy.2015.12.011

Cited by 27 publications

(20 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the present study, we also found smoking resulted in more men developing moderate or severe symptoms. Eriguchi et al [14] applied the BED calculations in 1313 men treated with BT with or without EBRT. They found increased AUASS of 6.2 points at 3 months, which decreased to 0.6 points by 5 years.…”

Section: Discussionmentioning

confidence: 99%

“…In all, 1 842 men with T1-T3 prostate cancer were treated by BT and followed for a minimum of 5 years (mean 9.4, range [5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22] and completed a pre-treatment AUASS. Of these, 1110 (60.3%) had minimal urinary symptoms (AUASS 0-7).…”

Section: Methodsmentioning

confidence: 99%

“…In all, 1842 men had completed both the initial pre-implantation and last AUASS assessment. A total of 1110 (60.3%) men had minimal initial urinary symptoms (AUASS of 0-7), 641 (34.8%) moderate symptoms (AUASS of [8][9][10][11][12][13][14][15][16][17][18][19] and 91 (4.9%) severe symptoms (AUASS of 20-35). The QOL score was 0-2 in 1420 (77.1%) men, 3 in 254 (13.8%), and 4-6 in 168 (9.1%).…”

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations

Factors influencing long‐term urinary symptoms after prostate brachytherapy

et al. 2018

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Factors influencing long‐term urinary symptoms after prostate brachytherapy

et al. 2018

View full text Add to dashboard Cite

show abstract

“…The International Prostate Symptoms Score (IPSS (28)) thus became widely used to score obstructive symptoms and generate an overall assessment of urinary functionality (15,(29)(30)(31)(32)(33)(34)(35)(36)(37)(38)(39)(40)(41)(42). Urinary incontinence can be prospectively assessed by the International Consultation on Incontinence Modular Questionnaire Short Form (ICIQ-SF (43)), which also includes the patient's perception of the impact of incontinence on quality of life (14,44).…”

Section: Is the Patient's Point Of View Of Interest? Challenges In Mementioning

confidence: 99%

Understanding Urinary Toxicity after Radiotherapy for Prostate Cancer: First Steps Forward

Rancati

Palorini

Cozzarini

et al. 2017

Tumori

View full text Add to dashboard Cite

Tumori 2017; 103(5): [395][396][397][398][399][400][401][402][403][404] REVIEW -BONADONNA LECTURE SERIES may be differently related to the absorbed dose. For example, rectal bleeding arises as a serial effect and is mainly related to the absorption of high doses in small rectal mucosa volumes, whilst fecal incontinence is related to intermediate doses absorbed by large rectal volumes.The development of reliable models of radiation-induced toxicities along with the available level of technology has determined an efficient improvement of the treatment plans, even in dose-escalated or hypofractionated regimens. This is particularly true for moderate and severe rectal toxicities, which had an incidence close to 20% in the 1990s while in the most recent publications they have fallen below 7%-10%.However, an analogous result has not yet been reached in urinary symptoms. This is mainly due to the difficulty in sparing the bladder, which is partially but unavoidably included in the target volume, as well as to the clear lack of knowledge concerning the predictors of urinary toxicity. The main reason for this deficiency is probably the difficulty in following for a sufficiently long time a large number of patients whose clinical and dosimetry data need to be individually and prospectively collected with proper evaluation of urinary symptoms. Some important symptoms (e.g., incontinence) may indeed continuously arise after radiation therapy and their incidence reaches a plateau only many years (typically 5-8) after treatment. The fulfilment of reliable models of radiation-induced urinary sequelae is therefore made particularly challenging by the complexity of symptoms, their evolution over time, and the strong dependence on the baseline situation.It is widely acknowledged that radiation-induced toxicity is a multifactorial problem, depending not only on the delivered

show abstract

“…While brachytherapy has positive long-term oncological outcomes, there are clinical concerns. These include the incidence of post-treatment adverse effects such as lower urinary tract symptoms (LUTS) and quality of life (QOL) deterioration [ 2 , 4 – 11 ].…”

Section: Introductionmentioning

confidence: 99%

Assessment of lower urinary symptom flare with overactive bladder symptom score and International Prostate Symptom Score in patients treated with iodine-125 implant brachytherapy: long-term follow-up experience at a single institute

et al. 2017

View full text Add to dashboard Cite

BackgroundThe aim of this study was to evaluate the combined use of the overactive bladder symptom score (OABSS) and International Prostate Symptom Score (IPSS) as an assessment tool for urinary symptom flare after iodine-125 (125I) implant brachytherapy. The association between urinary symptom flare and prostate-specific antigen (PSA) bounce was investigated.MethodsChanges in the IPSS and OABSS were prospectively recorded in 355 patients who underwent seed implantation. The percentage distribution of patients according to the difference between the flare peak and post-implant nadir was plotted to define significant increases in the scores. The clinicopathologic characteristics, treatment parameters, and post-implant dosimetric parameters were compared between the non-flare and flare groups. PSA bounce was defined as an elevation of ≥0.1 ng/mL or ≥0.4 ng/mL compared to the previous lowest value, followed by a decrease to a level at or below the pre-bounce value.ResultsA clinically significant increase required an IPSS increase of at least 12 points and an OABSS increase of at least 6 points based on a time-course analysis of total scores and the QOL index. Assessment only by IPSS failed to detect 40 patients (11%) who had urinary symptom flare according to the OABSS. Univariate and multivariate analyses revealed that patients treated with higher biologically effective doses and those without diabetes mellitus had higher risks of urinary flare. There was no statistical correlation between the incidence and time of urinary symptom flare onset and that of a PSA bounce.ConclusionsTo our knowledge, this is the first report to prove the clinical potential of the OABSS as an assessment tool for urinary symptom flare after seed implantation. Our findings showed that persistent lower urinary tract symptoms after seed implantation were attributed to storage rather than to voiding issues. We believe that assessment with the OABSS combined with the IPSS would aid in decision-making in terms of timing, selection of a treatment intervention, and assessment of the outcome.Electronic supplementary materialThe online version of this article (doi:10.1186/s12894-017-0251-1) contains supplementary material, which is available to authorized users.

show abstract

Predictive factors for urinary toxicity after iodine-125 prostate brachytherapy with or without supplemental external beam radiotherapy

Cited by 27 publications

References 39 publications

Factors influencing long‐term urinary symptoms after prostate brachytherapy

Factors influencing long‐term urinary symptoms after prostate brachytherapy

Understanding Urinary Toxicity after Radiotherapy for Prostate Cancer: First Steps Forward

Assessment of lower urinary symptom flare with overactive bladder symptom score and International Prostate Symptom Score in patients treated with iodine-125 implant brachytherapy: long-term follow-up experience at a single institute

Contact Info

Product

Resources

About